Treatment Page 2 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Initial management with aflibercept, laser photocoagulation or observation in patients with diabetic eye disease?

Posted by on May 19, 2019 in Diabetes mellitus | 0 comments

In a nutshell This article investigated the rate of vision loss at 2 years among eyes with center involved-diabetic macular edema (CI-DME; vision loss in people with diabetes) initially managed with aflibercept (Eylea), laser photocoagulation (LP) or observation. The authors concluded that there was no significant difference in vision loss at 2...

Read More

Is sitagliptin added to insulin safe and effective in elderly patients with type 2 diabetes?

Posted by on May 19, 2019 in Diabetes mellitus | 0 comments

In a nutshell This article investigated the safety and effectiveness of sitagliptin (Januvia) in the management of type 2 diabetes (T2D) in elderly patients on insulin. The authors concluded that the addition of sitagliptin is effective and safe in all patients receiving it as add-on therapy to insulin.  Some background In type 2...

Read More

Abiraterone acetate plus prednisone: an evaluation of the long-term effectiveness in prostate cancer treated with hormonal therapy.

Posted by on May 18, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated if abiraterone acetate (Zytiga) and prednisone (Deltasone) added to androgen deprivation therapy (ADT) improve survival in patients with advanced prostate cancer. They found that this combination was effective at improving survival in these patients. Some background...

Read More

Is combined treatment with erlotinib and bevacizumab effective in non-small cell lung cancer?

Posted by on May 18, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness of erlotinib (Tarceva) and bevacizumab (Avastin) compared ti erlotinib alone in non-small cell lung cancer (NSCLC). They found that combined treatment improved survival after 12 months. Some background Non-small cell lung cancer (NSCLC) is a common type of lung cancer (LC)....

Read More

Ipragliflozin versus metformin for blood sugar control and fat reduction in type 2 diabetes

Posted by on May 17, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to compare the effectiveness of ipragliflozin compared to metformin in improving blood sugar control and reducing fat on organs in patients with type 2 diabetes (T2D) treated with sitagliptin. The main finding of the study was that ipragliflozin had greater reductions in fat but metformin had better blood sugar...

Read More

Stereotactic body radiotherapy improves treatment response in metastatic colorectal cancer

Posted by on May 16, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of stereotactic body radiotherapy (SBRT) in metastatic (spread to other parts of the body) colorectal cancer. Researchers suggested that SBRT is associated with improved tumor response and manageable side effects. Some background Colorectal cancer is the second most commonly diagnosed cancer in...

Read More

Perturbation treadmill training improves gait and balance of patients with Parkinson’s disease

Posted by on May 15, 2019 in Parkinson's Disease | 0 comments

In a nutshell This study investigated if postural perturbations during treadmill training (PPTT) improved gait in patients with Parkinson's disease (PD). Researchers suggested that PPTT improves the movement symptoms of these patients.  Some background Parkinson's disease (PD) affects the brain cells causing symptoms such as muscle...

Read More

Supraflex: A new ultra-thin drug releasing stent for patients with coronary artery disease

Posted by on May 11, 2019 in Coronary artery disease | 0 comments

In a nutshell The aim of this study was to compare Supraflex (a new ultra-thin drug releasing stent) with a standard drug releasing stent (Xience) in the treatment of coronary artery disease (CAD). The main finding of the study was that the Supraflex had similar effectiveness as Xience. Some background CAD means that the blood vessels to the...

Read More

Evaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma

Posted by on May 11, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated  isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...

Read More